Details for New Drug Application (NDA): 202025
✉ Email this page to a colleague
The generic ingredient in SILDENAFIL CITRATE is sildenafil citrate. There is one drug master file entry for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Summary for 202025
| Tradename: | SILDENAFIL CITRATE |
| Applicant: | Amneal Pharms |
| Ingredient: | sildenafil citrate |
| Patents: | 0 |
Pharmacology for NDA: 202025
| Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 202025
Suppliers and Packaging for NDA: 202025
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 202025 | ANDA | AvKARE | 42291-937 | 42291-937-90 | 90 TABLET in 1 BOTTLE (42291-937-90) |
| SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 202025 | ANDA | A-S Medication Solutions | 50090-1766 | 50090-1766-0 | 30 TABLET in 1 BOTTLE (50090-1766-0) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Feb 28, 2013 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
